Abnormal expression of IGF2, H19, and CDKN1C in hepatoblastoma, driven by imprinting defects and/or loss of heterozygosity at 11p15.5, was first observed nearly three decades ago [30–32]. Here, IGF2 is linked to hepatoblastoma.